

## **ARCIS TECHNOLOGY GROWTH FUND**

- Arcis Capital Partners LLC is a sector specialist firm with deep expertise in Artificial Intelligence (AI) and Technology honed over three decades of working with some of the world's most prestigious companies.
- Arcis Technology Growth Fund invests in growth-stage AI-Based Software and HealthTech ventures that have meaningful commercial revenue, significant growth potential and little technology risk.

## FUND SUMMARY

 Growth equity strategy has historically delivered superior risk-adjusted return across venture capital, growth equity and buyout. It offers the upside potential of venture capital and downside risk protections of buyout, per Cambridge Associates' "Growth Equity" Turns Out, It's All About the Growth (January 2019).

 The Fund is ILPA-compliant and benchmarked against Cambridge Associates Benchmark Index for the US VC funds from 2020 vintage. The Fund has delivered upper quartile unrealized profitability as of September 30, 2023. New investors participate pro rata in Fund's performance.

	PRIVATE EQUITY W US EXERCISE MANAGER	US Emergin	g Manager Best	Performance Aw	vard sociates Bench	mark Indices			
		Arcis	(net of fees, expenses and carried interest)						
PERFORMANCE VC. BENCHMARK		Technology Growth Fund LP	Upper Quartile	Pooled Return	Average	Median	Lower Quartile		
	Net IRR (%)	20.28	16.00	10.75	8.64	7.43	0.98		
	TVPI	1.48	1.35	1.24	1.22	1.16	1.02		
	DPI	0.00	0.02	0.05	0.05	0.00	0.00		

		Angel	Seed	Growth	Crossover	Buyout
	INVESTOR TYPE/STAGE	Angel Investors	Seed-Stage Investors	Series A Through C	Series C Though IPO/exit	Buyout Firms/Debt Financed
	INVESTMENT SIZE	US\$10K- \$250K	US\$250K- \$2M	US\$10M- \$50M	US\$50M- \$100M	Depends, Millions to Billions.
	HOLDING PERIOD	8-10 Years	6-8 Years	5-7 Years	>5 Years	3-5 Years
WHY GROWTH EQUITY?	RETURN EXPECTATIONS	+10x	+10x	+7x	+5x	+3x
	<b>RISK LEVEL</b>	High	High	Low	Low	Low
	PROFITABILITY	Pre-Revenue	Pre-Revenue	Post-Revenue to Profitable	Mostly Profitable	Profitable & Stabilized
	FIRMS INVOLVED (representative examples, for reference only)	Combinator 5000 startups VAngel initialized() böldstart ventures	SEQUOIA andreessen. horowitz usv A Redpoint. greylock	BainCapital Accel PSG INSIGHT PARTNERS	SoftBank TEMASEK COATUE TIGERGLOBAL DI CAPITAL PARTNERS ALKEON	KKR THE CARLYLE GROUP SILVERLAKE TPG WARBURG PINCUS THOMABRAVO

For general reference only. Sources: <u>WallStreetPrep</u> and ArcisCap research and analysis

Arcis Capital Partners LLC | www.arciscap.com | +1-212-634-7173 | info@arciscap.com

PCS-ARCIS 24.04.01.001

DISCLAIMERS: This material does not constitute an offer or solicitation to purchase an interest in the Fund or any related vehicle, which shall only be made via a confidential offering memorandum. An investment in the fund is speculative and is subject to a risk of loss, including risk of principal. There is no secondary market for interests in the Fund and none is expected to develop. No assurance can be given that the fund will achieve its objective or that an investor will receive a return of all or part of its investment. This material contains certain forward-looking statements and projections regarding the future performance and asset allocation of the Fund. These projections are included for illustrative purposes only, are inherently speculative as they relate to future events, and may not be realized as described. Returns for each investor and investment series will differ based on the timing of capital contributions. Past performance is not indicative of future results. Please note that information above is subject to change; this is for general, illustrative purposes only. Securities offered through Pinnacle Capital Securities, LLC, member FINRA/SIPC.



## **ARCIS TECHNOLOGY GROWTH FUND**

Company	Description	Total Funding To-Date <sup>1</sup>	Last or Current Round	Pre- money Valuation	Fund Target <sup>2</sup>	Fund Invested To-Date	Fund Target MOIC <sup>3,5</sup>	Fund Role	Fund's Key MOIC Breakpoints <sup>4, 5</sup>	Notable Investors & Co- investors
	Al-based SaaS for adaptive learning	\$53.00M+	с	\$180.00M	\$5M	\$0.506M	~8x	Direct Investor, Advisor	1x @ ~\$23M 4x @ ~\$760M	en del af Vækstfore
ntegrated endoscopy	Med device; single-use arthroscope	\$36.74M+	с	\$45.00M	\$10M	\$3.825M	~15x	Lead & Board Member	1.25x @ ~\$8M 4x @ ~\$128M	FOSUNPHARMA 复星医药
COHTEIN	Al-generated care plans for cognitive impairment	\$12.25M+	с	\$40.00M	\$10M	\$2.635M	~21x	Lead & Board Member	1x @ ~\$25M 4x @ ~\$290M	the Pirk Ceilin
NEUROSYN©	Al-Based neuro health diagnostics and therapeutics	\$13.62M+	в	\$25.00M	\$10M	\$1.100M	~22x	Lead & Board Member	1.5x @ ~\$39M 4x @ ~\$158M	Q QUADRAN
WAHYD	Tech-enabled logistics in emerging markets	\$5.40M+	A-4	\$48.50M	\$5M	\$1.500M	~12x	Lead & Board Member	3x @ ~\$155M 4x @ ~170M	
Cerebri <mark>≥</mark>	AI-based SaaS for business travel carbon footprint	\$26.00M+	B-1	\$8.10M	\$5M	\$0.593M	~5x	Direct Investor, Advisor	TBD	N12 MCROSOFT'S VENTURE FUND
Greene Lyon	E-recycling – sustainable chip repurposing	\$10.00M+	А	\$10.00M	\$5M	\$0.528M	~7x	Direct Investor, Advisor	1x @ ~\$11M 4x @ ~\$55M	generation capital

analysis of the available data 2.

Fund

based on the terms and conductors on the last cloud and resulting, fund taget in actively investig *j* otherwise Fund Invested To-Date, normal market conditions, exit horizon, typical equity dilutions from follow on investment rounds; TBD = To be determined based on follow-on investment in the company FOR ILLUSTRATIVE PURPOSES ONLY; there is no guarantee that Fund will achieve these results 5.

Primarily North American companies with proven business models,

anaysis or the available data Fund's target allocation for the company, to be invested over time subject to company's performance and availability of dry powder Based on Company's pre-investment pro-forma financial projections, normal market conditions, exit horizon, typical equity dilutions from follow-on investment rounds, and GP's scenario analysis

3.

	FOCUS	Primarily North American companies with proven business models, significant growth potential and little technology risk
	TARGET SECTORS	AI-Based Software & HealthTech
	TARGET FUND SIZE	\$100M
	MINIMUM COMMITMENT	\$1M for institutional and \$100k for individual investors
	FUND TERM	6-years base term from initial close, two 1-year extension options
	TARGET RETURN	30%+ IRR, 4x TVPI, all net of fees, expenses & carry
	PREFERRED RETURN	8%
d Terms	<b>GP COMMITMENT</b>	Up to 5% (1% is required) <sup>1</sup>
	FEES	2% per year Management Fee & 20% Carried Interest
	<b>CO-INVESTMENTS</b>	Available at GP's discretion
	FUND & GP DOMICILE	Fund and GP domiciled in Delaware, USA Non-US parallel vehicles setup for non-US investors
	OUTSIDE GENERAL COUNSEL	Davidoff Hutcher & Citron LLP
	FUND AUDIT AND TAX	Marcum LLP
	BANKING/CASH CUSTODY	JPMorgan Chase Bank, N.A.
	FUND ADMINISTRATOR	JTC America (formerly known as NES Financial)

**MANAGING BROKER-DEALER** Pinnacle Capital Securities, LLC (member FINRA/SIPC.)